A Long-Term, Prospective, Observational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT)
2025-03-10
عنوان الدراسة
ational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT)
داعم الدراسة
Astrazeneca
دواء الدراسة
Ultomiris (Ravulizumab)
رقم بروتوكول الدراسة
ALX-NMO-50
حالة الدراسة
Ongoing
موقع الدراسة
King Khalid University Hospital (Riyadh) ,King Abdulaziz Medical City NG (Jeddah),King Abdulaziz Medical City NG (Riyadh)
مرحلة الدراسة
4
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。